Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
2018 DISCLOSURE OF INTEREST INFORMATION
GINA BOARD OF DIRECTORS
Louis-Philippe Boulet MD - Chair
Eric D. Bateman, MD
Guy Brusselle, MD, PhD, FERS
Alvaro A. Cruz, MD
Mark FitzGerald, MD
Hiromasa Inoue, MD
Mark L. Levy, MD
Jiangtao Lin, MD
Soren Erik Pedersen, MD - Chair
Helen K. Reddel, MBBS, PhD
Arzu Yorgancioglu, MD
Helen K. Reddel, MBBS, PhD - Chair
Len Bacharier, MD
Eric D. Bateman, MD
Louis-Philippe Boulet MD
Guy Brusselle, MD, PhD, FERS
Dr. Roland Buhl
Mark FitzGerald, MD
Louise Fleming, MD
Hiromasa Inoue, MD
Jerry A. Krishnan, MD, PhD
Soren Erik Pedersen, MD
Aziz Sheikh, MD
Dr Fanny Wai-san Ko
GINA SCIENCE COMMITTEE
GLOBAL INIT IATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTERESTJanuary 1, 2018 - December 31, 2018
BackgroundThe Global Initiative for Asthma (GINA) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of asthma among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on asthma, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on asthma research.
The purpose of this document is to safeguard the interests of all GINA collaborators by an open disclosure of interests.
GINA StructureAt present, the GINA program is conducted through a GINA Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GINA documents and all members will be asked to complete this form.
Annual Declaration of InterestsThe following declarations are requested by GINA. Please complete the company name select in thecorresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GINA website after completion.
Definitions:
1. Grants: refers to any grant paid to your organization.
2. Personal Fees: refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
3. Shares: refers to any shares in asthma-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.
4. Non-Financial Support: In-kind assistance.
The private sector should not in any way be involved in any aspect of developing documents, includingcollecting, reviewing or accessing the literature or determining the content. Once documents have beenproduced asthma-related commercial organizations can be involved in their dissemination and audit, including support for publications.
GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Louis-Philippe BOULET Member of: Chair of the Board of Directors of the GINA Chair of the Global Initiative for Asthma (GINA Guidelines) Dissemination and Implementation Committee Are there any relevant financial interests to disclose? Here are some potential COI for 2018
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
AstraZeneca x Research grants for participation to multicentre
Boston Scientific x Research grants for participation to multicentre
GlaxoSmithKline x Research grants for participation to multicentre
Hoffman La Roche x
Research grants for participation to multicentre
Novartis x Research grants for participation to multicentre
Ono Pharma x Research grants for participation to multicentre
Sanofi Takeda x Research grants for participation to multicentre
AstraZeneca x Consulting and advisory boards
Novartis x Consulting and advisory boards
Methapharm x Consulting and advisory boards
AstraZeneca x Conference fees
GlaxoSmithKline x Conference fees
Merck Frosst x Conference fees
Novartis x Conference fees
Novartis x Support for participation in conferences and meetings
Takeda x Support for participation in conferences and meetings
AstraZeneca x
Nonprofit grants for production of educational materials
Boehringer-Ingelheim x
Nonprofit grants for production of educational materials
GlaxoSmithKline x
Nonprofit grants for production of educational materials
Merck Frosst x
Nonprofit grants for production of educational materials
Novartis x
Nonprofit grants for production of educational materials
GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Professor Eric D Bateman
Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes; see below
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
Novartis yes Advisory board Sanofi-Aventis yes Advisory board
ALK yes Consultancy & Lecture fee
ICON yes
Study oversight steering committee
Regeneron yes Advisory board
AstraZeneca yes Advisory board & lecture fees
Boehringer Ingelheim yes Lecture fee
GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Brusselle Guy
Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
AstraZeneca Yes Advisory boards and lecture fees
Chiesi Yes Advisory boards and lecture fees
GlaxoSmithKline Yes Advisory boards and lecture fees
Novartis Yes Advisory boards and lecture fees
Sanofi Yes Advisory boards
Teva Yes Advisory boards and lecture fees
Boehringer-Ingelheim Yes Advisory boards and lecture fees
GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Alvaro A. Cruz
Member of: GINA Board of Directors Are there any relevant financial interests to disclose?
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
GSK X* X *Investigator
initiated AstraZeneca X X X Boehringer-Ingelheim X X CHIESI X Merk, Sharp & Dohme X
DISCLOSURE OF FINANCIAL INTEREST Name: Mark FitzGerald, MD
Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes; see below
1. PERSONAL BENEFITS* Includes fees (for lectures, advisory committees, travel grants, or consultancy services) either intermittent or regular, from which you benefit personally.
Company < $10,000 > $10,000 Nature/Purpose of Payment
BI GSK AZ Novartis Teva Merck
X X X X X
X
Advisory board Consulting for study design Lectures, advisory board, Advisory board and lecture fees Advisory board Lecture fees
* Check category only; do not list the amount received.
2. SHARES* Includes shares in the asthma related pharmaceutical/medical device industry, excluding pension plans, mutual funds or unit trusts, held by a GINA member or family members (spouse and children < 18 years).
Company < $10,000 > $10,000
None
*Check category only; do not list the number of shares or $ amount. 3. NON-PERSONAL INTERESTS* Includes fees or grants paid to a GINA member and used for research, education, equipment, salaries, etc.
Company < $10,000 > $10,000 Nature/Purpose of Support
AZ GSK Merck Novartis Sanofi
X Research funds paid directly to UBC for all companies and all greater than $10,000
* Check category only; do not list amount of funding received.
I confirm that these forms are complete. Name: _______________________ (Choose one or both) ____GINA Board of Directors _____ GINA Science Committee
Signature: Date:
GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Hiromasa Inoue
Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose?
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
Nippon Boehringer Ingelheim X X Chugai Pharmaceutical X X Kyorin Pharmaceutical X X Novartis Pharma X X Ono Pharmaceutical X X MSD X Teijin Pharma X Pfizer Japan X Taiho Pharmaceutical X Mitsubishi Tanabe Pharma X AstraZeneca X GlaxoSmithKline X Sanofi X Sumitomo Dainippon Pharma X
Levy
GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Jiangtao Lin
Member of: GINA Board of Directors Are there any relevant financial interests to disclose? No
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST Name: Søren Pedersen
Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose?
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
AstraZeneca + Lectures ALK + Advisory board Thermofisher + Advisory board
GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST Name: Helen Reddel
Member of: GINA Board of Directors, GINA Science Committee Are there any relevant financial interests to disclose? Yes
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
AstraZeneca Yes Yes Yes No Advisory boards, steering committee, DSMB, independent medical education, medical writing support
Boehringer Ingelheim No Yes No No Independent medical education
GlaxoSmithKline Yes Yes No No DSMB Merck No Yes No No DSMB Novartis No Yes No No DSMB, advisory
board
GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST Name: Arzu Yorgancıoglu
Member of: GINA Board of Directors and D&I Committee Are there any relevant financial interests to disclose?
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
Astra Zeneca yes yes yes
Advisory board, Invited speaker grant to institution
GlaxoSmithKline no no yes Advisory board, Invited speaker
Novartis no yes yes
Advisory board, Invited speaker grant to institution
Boehringer Ingelheim no yes yes Invites speaker Sanofi no yes yes Advisory Board ALK no yes yes Advisory Board
MSD yes no no grant to institution
Chiesi no yes yes Advisory board, Invited speaker
Global Alliance against Chronic Respiratory Diseases (GARD)/WHO
no no yes
Support for travel to meetings Vice Chair
Turkish Thoracic Society no no yes
Support for travel to meetings GARD Turkey Coordinator
GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST Name: Leonard B Bacharier, MD
Member of: GINA Science Committee Are there any relevant financial interests to disclose? Yes
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
Teva X Advisory board
GlaxoSmithKline X Advisory board, speaker bureau
Novartis X Honoraria for lectures
AstraZeneca X
Honoraria for lectures, Advisory Board
DBV Technologies X DSMB Member
Sanofi X Honoraria for lectures
Regeneron X Honoraria for lectures
BoehringerIngelheim X
Development of educational materials
Vectura X Consultant fees
Buhl
GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST Name: Dr. Louise Fleming
Member of: GINA Science Committee Are there any relevant financial interests to disclose? Yes
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
Novartis
Attendance at standalone advisory boards and payment for lectures; all fees paid to institution
GSK
Attendance at standalone advisory boards; all fees paid to institution
Boehringer Ingelheim
Attendance at standalone advisory boards and payment for lectures; all fees paid to institution
Teva
Payment for lecture; all fees paid to institution
Astra Zeneca
Payment for lecture; all fees paid to institution
Sanofi
Attendance at standalone advisory boards; all fees paid to institution
Respiri UK
Attendance at standalone advisory boards; all fees paid to institution
GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST Name: Jerry Krishnan
Member of: GINA Science Committee Are there any relevant financial interests to disclose?
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
National Institutes of Health Patient Centered Outcomes Research Institute
Sanofi
X (Independent Data Monitoring Committee)
Vanguard mutual funds
GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST Name: Aziz Sheikh
Director of: Scottish Allergy and Respiratory Academy (SARA) and Asthma UK Centre for Applied Research Are there any relevant financial interests to disclose? Yes
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
Mylan Yes
Sponsorship for Scottish Allergy & Respiratory Academy (SARA) – a not-for-profilt training programme for healthcare professionals
Nutricia Yes Sponsorship for SARA
GSK Yes Sponsorship for SARA
Napp Yes Sponsorship for SARA
Mead Johnson Ltd Yes Sponsorship for SARA
Chiesi Yes Sponsorship for SARA
Bausch & Lomb Yes Sponsorship for SARA
GSK Yes
Travel support to attend scientific meeting
GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST Name: Fanny Wai San KO
Member of: GINA Science Committee Are there any relevant financial interests to disclose? Yes
Name of Entity Grant? Personal Fee?
Non-Financial Support? Other? Comments:
Boehringer Ingelheim (HK) Ltd. through CHEST Delegation Hong Kong and Macau limited: Support for attending the ERS 2018 conference
Attending conference
September 2018
Astra Zenaca through Hong Kong Thoracic Society: Support for attending the ATS 2018 conference
Attending conference
May 2018